Xeris Biopharma Holdings, Inc. $XERS Holdings Raised by Jump Financial LLC

Key Points

• Jump Financial LLC dramatically increased its investment in Xeris Biopharma by 1,371.4%, now holding 423,523 shares valued at approximately $2.3 million.
• Xeris Biopharma received positive analyst attention, with upgrades from multiple firms raising its target prices, including Leerink Partners increasing theirs from $7.00 to $9.00.
• The company reported better-than-expected earnings, with an EPS of ($0.01) and revenues of $67.71 million, exceeding estimates for the quarter.

Jump Financial LLC raised its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 1,371.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 423,523 shares of the company's stock after buying an additional 394,739 shares during the period. Jump Financial LLC owned about 0.27% of Xeris Biopharma worth $2,325,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of XERS. Wealth Enhancement Advisory Services LLC boosted its position in Xeris Biopharma by 92.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after purchasing an additional 14,986 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Xeris Biopharma during the 1st quarter worth about $12,240,000. Millennium Management LLC lifted its holdings in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after buying an additional 502,853 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of Xeris Biopharma in the 4th quarter valued at approximately $47,000. Finally, Raymond James Financial Inc. acquired a new position in Xeris Biopharma in the fourth quarter worth approximately $45,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on XERS shares. Leerink Partners lifted their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research note on Tuesday, August 19th. HC Wainwright assumed coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target on the stock. Oppenheimer upped their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Finally, Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.08.

Xeris Biopharma Trading Up 2.3%

NASDAQ XERS opened at $7.95 on Wednesday. Xeris Biopharma Holdings, Inc. has a 1 year low of $2.48 and a 1 year high of $8.02. The company has a fifty day simple moving average of $5.67 and a 200 day simple moving average of $4.91. The company has a market cap of $1.28 billion, a P/E ratio of -37.86 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch purchased 25,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the transaction, the insider directly owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Dawn Halkuff sold 42,500 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the transaction, the director owned 115,000 shares of the company's stock, valued at approximately $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.56% of the stock is currently owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.